Retatrutide: A Comprehensive Guide to the Weight Loss Drug
Descubra a "Visão Geral do Medicamento para Perda de Peso Retatrutide", um medicamento revolucionário em ensaios clínicos de Fase 3, apresentando resultados promissores com perda de peso de até 24,2%.
Reconstitution Guide: Learn how to safely reconstitute retatrutide — step-by-step instructions, dosage calculations, and safety checks. Read the full guide →
Visão Geral
Retatrutide é um agonista triplo de receptores hormonais que atua sobre os receptores de GLP-1, GIP e glucagon. Representa a próxima geração da farmacoterapia para a obesidade.
Key Information
Mecanismo
Agonismo triplo dos receptores de GLP-1 (supressão do apetite), GIP (sensibilização à insulina) e glucagon (oxidação de gorduras e termogênese).
Benefits
- Perda de peso de até 24,2%
- Agonista triplo de hormônios
- Maior eficácia em ensaios clínicos
Side Effects
- Náusea
- Diarreia
- Vômito
Contraindications
- Not studied in pregnancy
Evidence Summary
A Fase 2 mostrou perda de peso de 24,2% em 48 semanas. Os ensaios de Fase 3 TRIUMPH estão em andamento.
Research
Os ensaios de Fase 2 demonstraram perda de peso de até 24,2% em 48 semanas, o maior índice entre todos os peptídeos em ensaios clínicos.
Ver InvestigaciónSafety
Efeitos colaterais gastrointestinais semelhantes aos da classe GLP-1. Ainda em desenvolvimento na Fase 3.
Retatrutide Weight Loss Drug Overview
Retatrutide for weight loss is under study as a triple hormone receptor agonist. It acts on GLP-1, GIP, and glucagon receptors. This new weight loss drug retatrutide is a next-gen obesity drug candidate.
Key Information
- Also known as: LY3437943
- Sequence: triple agonist peptide
- CAS number: 2378660-54-7
- Molecular formula: C221H342N46O48
- Half-life: 6 days
- Use: shot under the skin
- Dose range: 1-12 mg each week
- Price range: $4.0–$35.0/mg
- Storage: keep cold at 2-8C
- Mix: mix with sterile water
- US status: investigational (Phase 3)
- Legal status: not yet FDA-approved
- Phase 3 TRIUMPH trials: ongoing
- Research papers: 1 indexed
Mechanism
Retatrutide acts on three targets.
- GLP-1 may curb appetite.
- GIP may help insulin use.
- Glucagon may help fat burn and heat production.
Benefits
- Up to 24.2% weight loss
- Triple hormone agonist
- Strong trial results
Side Effects
- Nausea
- Diarrhea
- Vomiting
Warnings
- Not studied in pregnancy
Evidence Summary
Phase 2 showed up to 24.2% weight loss at 48 weeks.
Phase 3 TRIUMPH trials are still ongoing.
Research
Phase 2 trials showed up to 24.2% weight loss at 48 weeks. That is the best result yet for a peptide in trials. View the research papers indexed on our research page.
Safety
Side effects were similar to those seen with the GLP-1 class.
Retatrutide medication is still in Phase 3 study.
Legal Status
Still under study. Not yet FDA-approved. In Phase 3 TRIUMPH trials.
Frequently Asked Questions About Retatrutide
What is Retatrutide?
Retatrutide is a research peptide. It is also known as LY3437943. It is a retatrutide triple hormone receptor agonist being studied for weight loss. It is being studied for medical use. It is also sold by research chemical vendors.
How does Retatrutide work?
It acts on GLP-1, GIP, and glucagon receptors. The retatrutide GLP-1 effect may curb appetite. GIP may help insulin use. Glucagon may help fat burn and heat.
Is retatrutide a GLP 3 drug?
No. Search terms like glp retatrutide, retatrutide glp 3, glp3 retatrutide, and retatrutide glp-1 are common. They do not describe a standard drug class. Retatrutide is better described as a triple hormone receptor agonist.
What is the recommended dosage for Retatrutide?
The most studied dose range is 1-12 mg each week. Dose plans vary by study goal. Read published studies first, and start low. Retatrutide should only be used in controlled research settings.
Where can I buy Retatrutide?
PepsReview lists retatrutide weight loss pricing from many vendors. Check the Vendors tab for a price compare table with cost per milligram, purity, COA status, and stock. User reviews from real buyers are on each vendor profile page.
Is Retatrutide legal?
US status: investigational, Phase 3. It is not yet FDA-approved. It is in Phase 3 TRIUMPH trials.
What are the side effects of Retatrutide?
Reported side effects include nausea, diarrhea, and vomiting. Always review safety data and published studies before use.
Key Research Papers on Retatrutide
The following peer-reviewed studies and clinical trials are indexed in our research library for Retatrutide. Each paper links to a short summary with key findings, study design, and publication data.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — N Engl J Med, 2023 (450 citations)
Related Weight Loss / Metabolic Peptides
Other peptides in the weight loss / metabolic group may be useful for comparison research:
- Semaglutide — GLP-1 receptor agonist for weight loss and diabetes management
- Tirzepatide — GIP + GLP-1 dual agonist, once-weekly injectable
- Survodutide — Dual GLP-1/glucagon agonist in development
- Liraglutide — First-gen GLP-1 agonist, daily injection
- AOD-9604 — Modified growth hormone fragment for fat burning
Key Research Papers on Retatrutide: A Comprehensive Guide to the Weight Loss Drug
The following peer-reviewed studies and clinical trials are indexed in our research library for Retatrutide: A Comprehensive Guide to the Weight Loss Drug. Each paper links to a detailed summary with key findings, study design, and publication metadata.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — N Engl J Med, 2023 (450 citations)
- The power of three: Retatrutide's role in modern obesity and diabetes therapy — Eur J Pharmacol, 2024 (40 citations)
- Retatrutide-A Game Changer in Obesity Pharmacotherapy — Biomolecules, 2025 (20 citations)
Related Weight loss / Metabolic Peptides
Other peptides in the weight loss / metabolic category that may be of interest for comparative research:
Vendor Price Comparison
| Producto | Vendedor | Tamaño | Precio | $/mg | Pureza | COA | Stock | Visitar |
|---|---|---|---|---|---|---|---|---|
| Retatrutide 20mg | 20.0mg | $71.00 | $3.55 | 99.7% | SideChain Analytics (HPLC-MS/MS) (1d) | In Stock | Visitar | |
| GLP-3R 20mg Research Peptide | 20.0mg | $78.00 | $3.90 | 99% | — | In Stock | Visitar | |
| Retatrutide 10mg | 10.0mg | $52.00 | $5.20 | 99.7% | SideChain Analytics (HPLC-MS/MS) (1d) | In Stock | Visitar | |
| Retatrutide 30mg | 30.0mg | $199.00 | $6.63 | 99%+ | — | In Stock | Visitar | |
| Retatrutide 10mg | 10.0mg | $69.00 | $6.90 | 99%+ | — | In Stock | Visitar | |
| Retatrutide 20mg | 20.0mg | $179.00 | $8.95 | 99%+ | — | In Stock | Visitar | |
| Retatrutide 10mg | 10.0mg | $121.00 | $12.10 | 99%+ | Janoshik (7d) | In Stock | Visitar | |
| Retatrutide 10mg | 10.0mg | $139.99 | $14.00 | 99%+ | — | In Stock | Visitar |
Write a Review
Login to write a review
You need an account to share your experience with Retatrutide: A Comprehensive Guide to the Weight Loss Drug.
CadastrarRating Breakdown
Based on 3 avaliações.
Avaliações
Started taking Reta in May 2026 and 3 months later I'm down 33 lbs. Taking 6mg but weight loss has gotten slower. Thinking about going up to 8mg. The triple agonist mechanism is unreal.
Reta reversed my type 2 diabetes. A1C normalized within 4 months. Also lost 25 lbs. The heart rate increase is real though - monitoring that closely with my doctor.
Down 28 lbs in 4 months. The weight loss is unmatched but increased heart rate is a real side effect. Also noticed it blunted my dopamine - lost interest in unhealthy habits which was actually positive.
Community Discussions on Retatrutide
Join the conversation in our peptide community forum. Real users share their retatrutide experiences, dosing schedules, results, and tips.
View all Retatrutide forum discussions